SVFC Raises Capital For Strategic Growth 3/13/201

SVFC Raises Capital For Strategic Growth

3/13/2014 9:10:38 AM

NEW YORK, NY--(Marketwired - March 12, 2014) - IntelliCell BioSciences, Inc. ("IntelliCell" or the "Company") (OTCQB: SVFC), a regenerative medicine company utilizing adult autologous vascular cells (SVFCs) derived from the blood vessels found in adipose tissue, announced today that it has closed on a round of financing from Yorkville Advisors, LLC.

IntelliCell's Chief Executive Officer, Dr. Steven Victor, remarked, "This is a turning point for IntelliCell BioSciences. With the infusion of this capital, we will not only be able to fully open our New York flagship center, but also open an additional strategically placed remote cellular lab. We believe this will allow us to implement our business model."

According to Mark Angelo, "We are pleased to have closed this transaction with IntelliCell and look forward to working with management over the course of our investment."

Owen May stated, "We are extremely excited about IntelliCell BioSciences's stem cell technology and we believe that the new relationship with the Andrews Research and Education Foundation will be a pivotal step in better assessing the use of this therapy in sports medicine."

About IntelliCell Biosciences

IntelliCell is a pioneering regenerative medicine company focused on the expanding regenerative medical markets using adult autologous stromal vascular fraction cells (SVFCs) derived from the blood vessels in the adult adipose tissue. IntelliCell Biosciences has developed its own patented technology and protocol to separate adult autologous vascular cells from adipose tissue without the use of enzymes. IntelliCell will also be seeking to develop technology-licensing agreements with technology developers, universities, and international business entities